MPS Pharma Ltd
Mon 21/09/2026,16:1:0 | BSE : ADVIKLA
Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.
Market Data
Essential tool: analyze, trade, manage, decide.
Open
₹ 2.08
Previous Close
₹ 2.08
Volume
400
Mkt Cap ( ₹ Cr)
₹ 3.98
High
₹ 2.08
Low
₹ 2.08
52 Week High
₹ 2.08
52 Week Low
₹ 1.57
Book Value Per Share
₹ -0.08
Dividend Yield
₹ 0.00
Face Value
₹₹10.00
What's Your Call?
Collective community sentiment on MPS Pharma Ltd
Your Vote -
Buy
50.00%
Hold
0.00%
Sell
50.00%
50.00%
2 users have voted
Option Chain
Analyzes market sentiment, predicts MPS Pharma Ltd' movement.
NO_RECORD_FOUND
News
Media spotlight triggers stock stock attention, sentiment.
-
MPS Pharma - Notice Of Book Closure
-
MPS Pharma - Notice Of Book Closure
-
MPS Pharma - Notice Of The 32Nd Annual General Meeting For The Financial Year 2025-26
-
MPS Pharma - Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 -
-
MPS Pharma - Reg. 34 (1) Annual Report.
-
MPS Pharma - Announcement under Regulation 30 (LODR)-Change in Management
-
MPS Pharma - Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s
-
MPS Pharma - Shareholder Meeting- AGM To Be Held On 29Th September, 2026
-
MPS Pharma - Board Meeting Outcome for Outcome Of Board Meeting Pursuant To Regulation 30 Read With Schedule III Of The SEBI
-
MPS Pharma - Board Meeting Intimation for Notice Of Board Meeting
-
MPS Pharma - Submission Of Outcome Of Board Meeting And Unaudited Results For The Quarter Ended 30.06.2026
-
MPS Pharma - Board Meeting Outcome for Outcome Of Board Meeting Held On 13.08.2026
-
MPS Pharma - Board Meeting Intimation for Notice Of Board Meeting To Consider The Un-Audited Financial Results Of The Company
-
MPS Pharma has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2026
-
MPS Pharma - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Key fundamentals
Evaluate the intrinsic value of MPS Pharma Ltd stockÂ
| Name | March-26 | March-25 | March-24 | March-23 | March-22 |
|---|---|---|---|---|---|
| Assets | 7.5925 | 8.5386 | 9.2429 | 9.5556 | 9.6338 |
| Liabilities | 7.5925 | 8.5386 | 9.2429 | 9.5556 | 9.6338 |
| Equity | 19.1114 | 19.1114 | 19.1114 | 19.1114 | 19.1114 |
| Gross Profit | -0.9459 | -0.7643 | -0.7989 | -0.9479 | -0.6759 |
| Net Profit | -1.02 | -0.8978 | -0.831 | -1.0503 | -0.1415 |
| Cash From Operating Activities | -0.5897 | -0.5699 | -0.6331 | -0.8655 | -4.3403 |
| NPM(%) | 0 | 0 | 0 | 0 | -437.31 |
| Revenue | 0 | 0 | 0 | 0 | 0.0323 |
| Expenses | 0.9459 | 0.7643 | 0.7989 | 0.9479 | 0.7083 |
| ROE(%) | 601.76 | 529.73 | 490.29 | 619.69 | 83.52 |
Corporate Action
| XD-Date | Dividend-Amount | Dividend-% | Dividend Yield(%GE) | Price on that day |
|---|
Peers
Other companies within the same industry or sector that are comparable to MPS Pharma Ltd
| Company | Price | Price (% change) | pe(x) | EV/EBITDA(x) | ROE(%) | ROCE(%) |
|---|---|---|---|---|---|---|
| Albert David Ltd | 847.00 | 0.83 | 21.47 | 1.19 | -26.19 | 0.59 |
| Lotus Eye Hospital and Institute Ltd | 116.25 | 0.65 | 1642.43 | 4.33 | 0.39 | 0.00 |
| Bharat Immunological and Biologicals Corporation Ltd | 13.98 | 0.79 | 0.00 | 8.98 | -39.50 | 0.00 |
| Astec Lifesciences Ltd | 793.90 | 10.30 | 0.00 | 4.63 | -363.14 | 0.00 |
Company Info
MPS Pharmaa Limited (formerly Advik Laboratories LImited) was incorporated in the year 1994 with a group of dedicated professionals & commenced commerical production in 1997. Company manufacture and export a wide range of pharmaceutical medicines that includes antihypertensive medicines, antihypertensive tablets, antifungal tablets, antifungal capsules, erectile dysfunction drugs, sedatives, corticosteroid medicines, antimalarials, anthelminthics, antipyretic & anti-inflammatory and antibacterials & antibiotics.Achievements-MPS Pharmaa Limited is an ISO 9001:2008 Certified Company & WHO-GMP Certified Company, follows the good manufacturing practices recommended by the World Health Organisation and constantly makes effort to improve upon them.2003- Advik Laboratories launches 'Biosulf', a biotech product- Advik Laboratories Ltd has informed that it has launched the product Enerva in various strengths for which permission has already been granted for export by the Director General of Health Services, Govt. of India.-Advik Labs wins Rs 20 cr export order from Qmedic.-The Company Ties up with M/s Max Medical of UK for reaching a sales tie up for UK & Europe.2008-The Company the email id designated exclusively for grievance redressal division / compliance officer: Investor@advikindia.com2023-Company name has changed to MPS Pharma Ltd. from Advik Laboratories Ltd.
MPS Pharmaa Limited (formerly Advik Laboratories LImited) was incorporated in the year 1994 with a group of dedicated professionals & commenced commerical production in 1997. Company manufacture and export a wide range of pharmaceutical medicines that includes antihypertensive medicines, antihypertensive tablets, antifungal tablets, antifungal capsules, erectile dysfunction drugs, sedatives, corticosteroid medicines, antimalarials, anthelminthics, antipyretic & anti-inflammatory and antibacterials & antibiotics.Achievements-MPS Pharmaa Limited is an ISO 9001:2008 Certified Company & WHO-GMP Certified Company, follows the good manufacturing practices recommended by the World Health Organisation and constantly makes effort to improve upon them.2003- Advik Laboratories launches 'Biosulf', a biotech product- Advik Laboratories Ltd has informed that it has launched the product Enerva in various strengths for which permission has already been granted for export by the Director General of Health Services, Govt. of India.-Advik Labs wins Rs 20 cr export order from Qmedic.-The Company Ties up with M/s Max Medical of UK for reaching a sales tie up for UK & Europe.2008-The Company the email id designated exclusively for grievance redressal division / compliance officer: Investor@advikindia.com2023-Company name has changed to MPS Pharma Ltd. from Advik Laboratories Ltd.
Read More
Parent Organisation
MPS Pharma Ltd.
Founded
09/09/1994
Managing Director
Mr.Peeyush Kumar Aggarwal
NSE Symbol
FAQ
The current price of MPS Pharma Ltd is
The 52-week high for MPS Pharma Ltd is
The market capitalization of MPS Pharma Ltd is currently This value can fluctuate based on stock price movements and changes in the number of shares outstanding.
To buy MPS Pharma Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.
To invest in MPS Pharma Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase MPS Pharma Ltd shares.
The CEO of MPS Pharma Ltd is Mr.Peeyush Kumar Aggarwal, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.
